Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2023-09-28 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
监事会关于公司2023年限制性股票激励计划首次授予激励对象名单（首次授予日）的核查意见
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from the supervisory board regarding the verification opinion on the initial grant list of restricted stock incentive plan for 2023. It discusses compliance with relevant laws and regulations, eligibility of incentive recipients, and details of the stock grant (number of shares, price, and date). The document is an announcement related to a capital incentive plan, specifically about the issuance of restricted stock to employees. It does not contain financial statements or detailed financial performance data, nor is it a full report or presentation. It is an update on a capital/financing activity (stock incentive grant). Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short and it is not merely announcing a report publication, so it is not RPA or RNS. Confidence is high given the clear content and context.
2023-09-28 Chinese
独立董事关于公司第三届董事会第十四次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion statement regarding adjustments and initial grants under the company's 2023 restricted stock incentive plan. It references compliance with relevant laws and company governance documents, and it is an official announcement of the independent directors' approval and opinions on these matters. The document is short (1193 characters) and does not contain financial statements or detailed financial data. It is not a full report but an announcement related to governance and incentive plan matters. This fits best under Regulatory Filings (RNS) as it is a formal regulatory announcement about corporate governance and stock incentive plan adjustments, not a full management report or financial report.
2023-09-28 Chinese
关于调整公司2023年限制性股票激励计划相关事项的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding adjustments to the company's 2023 restricted stock incentive plan. It details board and supervisory meetings, approvals, and legal opinions related to the stock incentive plan adjustments. The content focuses on changes to the stock incentive plan, including the number of shares and participants, and confirms compliance with relevant laws and regulations. There is no financial report, earnings data, or detailed financial statements. The document is a formal announcement about management and board decisions related to stock incentives, which fits best under Board/Management Information (MANG) as it concerns management-level decisions and disclosures about stock incentive plans.
2023-09-28 Chinese
第三届监事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 13th meeting of the third Supervisory Board of Xiamen Aide Biological Pharmaceutical Technology Co., Ltd. It details the approval of adjustments to the 2023 restricted stock incentive plan and the initial grant of restricted stock to eligible recipients. The document includes voting results and compliance with relevant laws and regulations. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is a formal meeting resolution announcement related to management decisions on stock incentives. This fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company management or board bodies. The document length is short (1588 characters), and it is not a report publication announcement or regulatory filing. Therefore, the classification is MANG with high confidence.
2023-09-28 Chinese
上海市锦天城律师事务所关于厦门艾德生物医药科技股份有限公司2023年限制性股票激励计划调整与授予事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment and grant of a 2023 restricted stock incentive plan for a company. It discusses legal compliance, approvals by the board and supervisory committee, and conditions for the stock grant. There are no financial statements, earnings data, or regulatory filings typical of annual or interim reports. The document is a standalone legal opinion related to a specific corporate action (stock incentive plan adjustment and grant). This fits best under the category of Regulatory Filings (RNS) as it is a legal opinion letter and does not constitute a financial report or other specific filing type.
2023-09-28 Chinese
2023年限制性股票激励计划首次授予激励对象名单（首次授予日）
Board/Management Information Classification · 95% confidence The document is titled as a list of recipients for a 2023 restricted stock incentive plan initial grant by Xiamen Aide Biomedical Technology Co., Ltd. It details the allocation of restricted stock to core management and technical personnel, including names, positions, and share quantities. There is no financial statement, earnings data, or regulatory certification. The content is focused on stock incentive allocation to management and key employees, which is a form of management information related to equity incentives. It is not an announcement of a report, nor a full financial report or audit. Therefore, the document fits best under Board/Management Information (MANG) as it relates to management incentives and stock grants.
2023-09-28 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.